In patients with non–large vessel occlusion acute ischemic stroke and salvageable brain tissue, administering intravenous tenecteplase between 4.5 and 24 h after stroke onset helps increase the chances of having an excellent functional outcome, although it contributes to an increased risk of symptomatic intracranial haemorrhage, according to a study.